Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - powder for solution for injection - aztreonam 1 g - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - aztreonam 1 g; aztreonam 1 g - powder for injection - 1 g - active: aztreonam 1 g excipient: arginine active: aztreonam 1 g excipient: arginine - for the treatment of infections caused by susceptible gram-negative microorganisms. it has been used successfully to treat: urinary tract infections (including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to the pathogens resistant to the aminoglycosides, cephalosporins or penicillins); lower respiratory tract infections (including pneumonia and bronchitis); bacteraemia/septicemia; bone and joint infections; skin and skin-structure infections (including those associated with postoperative wounds, ulcers and burns); intra-abdominal infections (including peritonitis); gynaecologic infections (including pelvic inflammatory disease, endometritis, and pelvic cellulitis); gonorrhoea (acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of n.gonorrhoeae). before instituting treatment with azactam, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. treatment with azactam may be started empirically before results of the susceptibility testing are available. concurrent therapy: in seriously ill patients, additional antibiotic therapy should be initiated concurrently with azactam to provide broad-spectrum coverage before identification and susceptibility testing results of the causative organism(s) are known. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an amino-glycoside because of synergistic action. these agents are also synergistic in vitro against many strains of enterobacteriaceae, and other gram-negative aerobic baccilli. however, this enhanced activity is not predictable.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - aztreonam lysine - powder and solvent for nebuliser solution - 75mg